Airway Medix S.A.

Airway Medix S.A.

AWM.WA
Airway Medix S.A.PL flagWarsaw Stock Exchange
0.27
PLN
+0.00
- -
31.43MMarket Cap
Airway Medix S.A.
AWM.WA
(Warsaw Stock Exchange)

Recent

price

0.27

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.05
- -
-0.03
-0.04
0.01
-0.03
-0.02
-0.04
-0.13
-0.65
-0.05
-0.16
0.02
-0.05
Basic EPS, GAAP
-0.13
- -
-0.12
-0.16
-0.15
-0.11
-0.03
-0.12
-0.09
-0.01
-0.07
-0.1
-0.04
-0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
0.91
0.96
0.9
0.51
0.48
0.44
0.31
-0.34
-0.36
-0.4
-0.21
-0.18
Book Value per Share
- -
- -
-0.12
0.34
0.26
0.36
0.22
0.09
-0.29
-0.26
-0.22
-0.33
-0.21
-0.18
Tangible Book Value per Share
37
- -
50
54
58
58
58
58
58
58
61
74
88
111
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-4,070.18
- -
-285.45
-568.37
-752.92
- -
-2,912.63
-20,741.67
-42,358.33
-147,775
-3,752.81
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
- -
-2
-2
1
-2
-1
-2
-7
-38
-3
-12
2
-6
Net Income, GAAP
- -
- -
- -
- -
18.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-3,536.84
- -
-220.85
-462.93
-923.74
- -
-39,909.47
-27,300
-97,791.67
43,650
-6,634.83
Profit Margin (%)
- -
1
-1
21
12
10
4
9
-16
-7
-11
-15
-16
-17
Working Capital
- -
- -
5
3
- -
- -
3
3
- -
7
- -
7
- -
- -
LT Debt
- -
17
16
24
25
34
33
31
22
-15
-13
-24
-8
-10
Total Equity
- -
- -
- -
- -
3.08
- -
- -
- -
- -
- -
- -
- -
-494.02
- -
Return on Invested Capital (%)
- -
- -
- -
- -
1.72
- -
- -
- -
- -
- -
- -
- -
-50.75
- -
Return on Capital (%)
- -
- -
-3.72
-4.17
1.22
-4.96
-4.7
-8.77
-33.84
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14
13
13
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
115
Market Capitalization
36
30
34

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
2
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
19
17
18
Payables & Accruals
- -
- -
- -
ST Debt
14
13
13
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-10.36%
-37.76%
-65.05%
Free Cash Flow
80.63%
109.05%
-52.44%
Net Income, GAAP
19.5%
135.01%
-114.88%
Sales/Revenue/Turnover
- -
- -
-66.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.08
-0.02
- -
-0.16
2025
-0.01
- -
-0.02
- -
0.02
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Airway Medix S.A. (WSE: AWM) develops and commercializes innovative medical devices focused on airway management and respiratory care. The company offers the AIRWAY MEDIX Pressure Chamber (AMPC) system, a closed suction catheter designed to minimize ventilator-associated pneumonia risks by enabling continuous endotracheal tube cuff pressure control; the MAD-gam catheter, a mucus aspiration device for selective suctioning in intubated patients; and the AM-CPAP device, a compact continuous positive airway pressure system for noninvasive ventilation support. These products target intensive care units, emergency departments, and respiratory therapy settings, serving hospitals and clinics primarily in Europe with expanding distribution in select international markets. Founded in 2015 and headquartered in Warsaw, Poland, Airway Medix operates as a clinical-stage medtech firm with no reported subsidiaries or parent relationships. In recent developments, the company advanced toward commercialization of its AMPC system following successful multicenter clinical trials and secured CE Mark approval in late 2023, enabling European market entry; it also formed strategic distribution partnerships in key EU countries and raised Series B funding exceeding EUR 10 million in 2024 to support manufacturing scale-up and regulatory submissions for U.S. FDA clearance.